JP2020524166A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524166A5 JP2020524166A5 JP2019570553A JP2019570553A JP2020524166A5 JP 2020524166 A5 JP2020524166 A5 JP 2020524166A5 JP 2019570553 A JP2019570553 A JP 2019570553A JP 2019570553 A JP2019570553 A JP 2019570553A JP 2020524166 A5 JP2020524166 A5 JP 2020524166A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- methyl
- deficiency
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1709824.5 | 2017-06-20 | ||
| GBGB1709824.5A GB201709824D0 (en) | 2017-06-20 | 2017-06-20 | Novel Compounds |
| GB1803561.8 | 2018-03-06 | ||
| GBGB1803561.8A GB201803561D0 (en) | 2018-03-06 | 2018-03-06 | Novel compounds |
| PCT/GB2018/051691 WO2018234775A1 (en) | 2017-06-20 | 2018-06-19 | Substituted cyanopyrrolidines with activity as dub inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524166A JP2020524166A (ja) | 2020-08-13 |
| JP2020524166A5 true JP2020524166A5 (https=) | 2021-08-05 |
| JP7208931B2 JP7208931B2 (ja) | 2023-01-19 |
Family
ID=62778943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570553A Active JP7208931B2 (ja) | 2017-06-20 | 2018-06-19 | Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11059809B2 (https=) |
| EP (1) | EP3642196B1 (https=) |
| JP (1) | JP7208931B2 (https=) |
| CN (1) | CN110831936B (https=) |
| WO (1) | WO2018234775A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522267D0 (en) * | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| US11014912B2 (en) | 2016-09-27 | 2021-05-25 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物 |
| JP7530889B2 (ja) | 2018-10-05 | 2024-08-08 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン |
| JP2024544660A (ja) | 2021-12-01 | 2024-12-03 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン |
| WO2023149768A1 (ko) * | 2022-02-07 | 2023-08-10 | 주식회사 내쉬원 | 탈유비퀴틴화효소 억제제를 포함하는 소포체 스트레스 관련 질환 예방 또는 치료용 약학적 조성물 |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1272467A4 (en) | 2000-04-06 | 2003-05-07 | Merck Frosst Canada Inc | Cathepsin cysteine protease inhibitors |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| TWI433677B (zh) | 2007-06-04 | 2014-04-11 | Avila Therapeutics Inc | 雜環化合物及其用途 |
| US20090264431A1 (en) | 2007-08-20 | 2009-10-22 | Palovich Michael R | Novel cathepsin c inhibitors and their use |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| WO2009129371A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| WO2009129365A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| RS58361B1 (sr) | 2013-07-31 | 2019-03-29 | Merck Patent Gmbh | Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba |
| US9963444B2 (en) | 2014-05-19 | 2018-05-08 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof |
| US20170095457A1 (en) * | 2014-05-27 | 2017-04-06 | David Lonergan | Compositions and methods of delivery of deubiquitinase inhibitors |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| CA2976741C (en) * | 2015-03-30 | 2023-01-17 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| WO2017009650A1 (en) | 2015-07-14 | 2017-01-19 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| CN108884068B (zh) | 2016-03-24 | 2021-02-26 | 特殊治疗有限公司 | 作为dub抑制剂的1-氰基-吡咯烷衍生物 |
| US11014912B2 (en) | 2016-09-27 | 2021-05-25 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
-
2018
- 2018-06-19 CN CN201880040925.5A patent/CN110831936B/zh active Active
- 2018-06-19 US US16/615,709 patent/US11059809B2/en active Active
- 2018-06-19 EP EP18734921.2A patent/EP3642196B1/en active Active
- 2018-06-19 WO PCT/GB2018/051691 patent/WO2018234775A1/en not_active Ceased
- 2018-06-19 JP JP2019570553A patent/JP7208931B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524166A5 (https=) | ||
| JP2019532938A5 (https=) | ||
| JP2019533659A5 (https=) | ||
| JP2019503362A5 (https=) | ||
| JP2019501142A5 (https=) | ||
| US20240246915A1 (en) | Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | |
| JP2020521730A5 (https=) | ||
| JP2019532950A5 (https=) | ||
| US10000511B2 (en) | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | |
| JP2022552444A5 (https=) | ||
| JP7045985B2 (ja) | Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法 | |
| JP2011515337A5 (https=) | ||
| JP2019532945A5 (https=) | ||
| JP7328323B2 (ja) | ＳＭＡＲＣＡ２／ＢＲＭ ＡＴＰａｓｅ阻害剤としての尿素化合物及び組成物 | |
| JP2019518766A5 (https=) | ||
| US9649314B2 (en) | Pyrimido[4,5-b]quinoline-4,5(3H,10H)-diones | |
| JP2019504009A5 (https=) | ||
| JP2024517498A5 (https=) | ||
| TW202313050A (zh) | 組合療法 | |
| JP2023527025A5 (https=) | ||
| US9896448B2 (en) | Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives | |
| JP5060285B2 (ja) | 固形腫瘍治療剤 | |
| JPWO2006101103A1 (ja) | 造血器腫瘍治療剤 | |
| WO2022109311A1 (en) | Methods and materials for increasing nicotinamide phosphoribosyltransferase activity | |
| WO2007054727A1 (en) | Combination of roscovitine and a hdca inhibitor to treat prolifeative diseases |